World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Rhea-AI Summary
NeuroSense (NASDAQ: NRSN) announced that Prof. Steven E. Arnold, a noted Alzheimer's expert and Professor of Neurology at Harvard Medical School, has joined its Scientific Advisory Board.
The company said Prof. Arnold brings biomarker-driven clinical development and translational neuroscience experience as NeuroSense advances its PrimeC programs in ALS and Alzheimer's disease. NeuroSense reported that its proof-of-concept Alzheimer's study (RoAD) showed a favorable safety and tolerability profile, and that clinical and biomarker outcomes from RoAD are expected in Q1 2026.
Positive
- RoAD proof-of-concept showed favorable safety and tolerability
- Clinical and biomarker outcomes expected in Q1 2026
- Prof. Steven E. Arnold joined the Scientific Advisory Board
Negative
- No efficacy or detailed biomarker results disclosed yet; outcomes pending Q1 2026
News Market Reaction
On the day this news was published, NRSN gained 12.43%, reflecting a significant positive market reaction. Argus tracked a peak move of +25.0% during that session. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $33M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NRSN was down 4.21% while close peers were mixed: TENX down 4.1%, ALLR up 4.5%, KZR up 0.8%, ITRM up 2.57%. Momentum scanner flagged ITRM, CVKD, and RVPH all moving up, underscoring that NRSN’s weakness diverged from several biotech peers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 22 | Alzheimer’s safety data | Positive | +3.8% | Phase 2 Alzheimer’s study showed favorable safety and tolerability with no serious events. |
| Dec 04 | Regulatory planning | Positive | -3.5% | Health Canada outlined steps toward a potential mid‑2026 NDS submission for PrimeC in ALS. |
| Nov 24 | FDA trial clearance | Positive | -3.6% | FDA authorized initiation of the pivotal Phase 3 PARAGON ALS trial under an IND amendment. |
| Nov 03 | Investor webinar | Neutral | -3.6% | Company scheduled a webinar to provide business, regulatory, and clinical program updates. |
| Oct 06 | Biomarker results | Positive | -6.4% | Phase 2b biomarker data showed statistically significant reductions in Alzheimer’s‑linked microRNAs. |
Recent history shows multiple positive clinical and regulatory updates followed by negative next-day moves, suggesting a pattern of the stock selling off on good news.
Over the last few months, NeuroSense has advanced PrimeC across ALS and Alzheimer’s. On Oct 6, 2025, positive Alzheimer’s biomarker data was followed by a -6.4% move. Later, FDA clearance for the pivotal ALS Phase 3 PARAGON trial on Nov 24, 2025 coincided with a -3.64% reaction. A favorable Alzheimer’s safety update on Dec 22, 2025 saw a +3.83% move. Today’s SAB appointment and reiterated Q1 2026 readout expectations fit into this ongoing clinical buildup.
Regulatory & Risk Context
An effective Form F-3 dated Oct 28, 2025 registers 333,334 ordinary shares for resale by a selling shareholder from a prior private placement. The company stated it will not receive any proceeds from these resale transactions. The shelf is effective through Oct 28, 2028 with 0 recorded usages in the provided context.
Market Pulse Summary
The stock surged +12.4% in the session following this news. A strong positive reaction aligns with building momentum around PrimeC’s Alzheimer’s program and broader ALS pipeline. Past news often saw selling pressure despite good updates, with several events followed by declines of 3–6%. A sharp upside move against that backdrop could reflect changing sentiment as Q1 2026 biomarker and clinical readouts approach, but investors may still weigh overhangs from registered resale shares and prior volatility.
Key Terms
biomarker medical
biomarker-driven clinical development medical
translational neuroscience medical
Alzheimer's disease medical
amyotrophic lateral sclerosis medical
proof-of-concept medical
AI-generated analysis. Not financial advice.
Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026
"Prof. Arnold's depth of experience in biomarker-driven clinical development and translational neuroscience aligns closely with how we are advancing our programs," said Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense. "His perspective will be valuable as we continue to execute across both Alzheimer's disease and ALS."
"PrimeC's multi-target mechanism addresses biological pathways that are highly relevant to Alzheimer's disease," said Prof. Steven E. Arnold. "I look forward to reviewing the forthcoming clinical and biomarker data and to contributing to the program as it moves forward."
NeuroSense recently concluded its proof-of-concept Alzheimer's disease study (RoAD), with top-line results demonstrating a favorable safety and tolerability profile. Clinical and biomarker outcomes from the study are expected in the first quarter of 2026.
About Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding the timing of the reporting of additional data from the study of PrimeC in Alzheimer's disease, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/world-renowned-alzheimers-expert-prof-steven-arnold-joins-neurosense-sab-302656417.html
SOURCE NeuroSense
FAQ
Who did NeuroSense (NRSN) add to its Scientific Advisory Board on Jan 8, 2026?
When will NeuroSense (NRSN) release clinical and biomarker outcomes from the RoAD study?
What did the RoAD proof-of-concept Alzheimer's study report for NeuroSense (NRSN)?
How does Prof. Steven E. Arnold's appointment affect NeuroSense's programs (NRSN)?
Does NeuroSense (NRSN) disclose efficacy results from the RoAD Alzheimer’s study yet?
